Novartis whips up flu vaccine quickly; Biogen, Genentech, GSK feud over anti-CD20 tech;

@FierceBiotech: PPD's BioDuro opens Shanghai discovery lab. FierceCRO story | Follow @FierceBiotech

@JohnCFierce: Amgen, Novartis aim to fuel biotech startups in alliance with Atlas Venture. Report | Follow @JohnCFierce

@RyanMFierce: PTC, bluebird join the IPO frenzy in biotech with genetic therapies. Story | Follow @RyanMFierce

> Novartis ($NVS) readied a vaccine against a new strain of flu in days. Article

> Stemline Therapeutics ($STML) and Cyclacel Pharmaceuticals ($CYCC) announced follow-on financings worth a combined $80 million. Brief

> Aridis Pharmaceuticals has scooped up antibody assets and tech from Kenta Biotech. Item

> It's another turn of the screw in an ongoing legal battle of Biogen Idec ($BIIB) and Genentech versus GlaxoSmithKline ($GSK) over intellectual property for anti-CD20 antibodies. Biogen and Genentech requested a rehearing of the case. Release

Medical Device News

@FierceMedDev: Shorter Tryton side branch stent wins CE mark. Article | Follow @FierceMedDev

@MarkHFierce: J&J is leaving the metal hip replacement business behind. Bloomberg broke a good one: Report | Follow @MarkHFierce

 @DamianFierce: Quest buys Humana's toxicology and clinical lab business. News | Follow @DamianFierce

> Thoratec wins FDA nod for HeartMate controller. Report

> Thermedical scores $5.5M in funding for tumor, heart ablation research. Item

> Vascular Solutions sues Boston Scientific for 'blatant' patent infringement. News

Pharma News

 @FiercePharma: Another pharma deal: Sweden's Recipharm mulls IPO or partial sale, Reuters says. UBS advising. News | Follow @FiercePharma

 @EricPFierce: EMA committee backs Bayer's Diane-35 birth control drug, even as off-label acne treatment. Article | Follow @EricPFierce

> Sanofi, France remain at odds over fate of 600 R&D jobs. Article

> India sets controversial price caps on 650 drugs. Story

> GSK tries novel approach in emerging markets: price cuts. Report

And Finally… 23andMe CEO Anne Wojcicki grabs the attention of a VC crowd by telling them of their higher-than-average chances of going bald. Blog